Germany's Curetis Adds $6.4M to Series A Financing to Prep MDx System for US Trials | GenomeWeb

By Ben Butkus

German molecular diagnostics firm Curetis said this week that it has netted an additional €4.5 million ($6.4 million) in its Series A financing round, raising its total to €24.5 million in three tranches.

Curetis will use the cash to accelerate the US commercialization of Unyvero, the company's benchtop automated DNA-testing platform, and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic resistance markers, company officials said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?